secwatch.observer — SEC 8-K summary
======================================

Issuer:     PANACEA LIFE SCIENCES HOLDINGS, INC. (PLSH)
CIK:        0001552189
Form:       8-K/A
Filed at:   2023-12-08T23:59:59+00:00
Accession:  0001493152-23-044203
Event type: m_and_a
Sentiment:  negative
Materiality: 0.75
Item codes: 9.01, 2.01
LLM model:  deepseek-v4-flash:cloud@v2

Panacea Life Sciences Holdings files N7 Enterprises financials showing losses and going concern
--------------------------------------------------------------------------------

- N7 had $326k revenue and $82k net loss in 2022; 6mo2023 revenue $1.18M, net loss $147k.
- Auditors express substantial doubt about N7's ability to continue as a going concern.
- Acquisition consideration: 784 preferred shares convertible into 7.84M common shares of Panacea.
- N7 started operations Nov 2022; negative cash flows and accumulated deficit noted.
- Pro forma financials combine Panacea and N7 for six months ended June 30, 2023 and year ended Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1552189/000149315223044203/0001493152-23-044203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1552189/000149315223044203/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-044203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer